Status:
ACTIVE_NOT_RECRUITING
Are Smokers Switching to Vaping at Lower Risk for Cancer? (Electronic Cigarettes and Cancer Risk)
Lead Sponsor:
University of Southern California
Collaborating Sponsors:
University of California
Conditions:
Cigarette Smoking
Eligibility:
All Genders
22-55 years
Phase:
NA
Brief Summary
This project will address a growing public health concern, namely, the health risks or benefits of e-cig use relative to cigarette smoking. The investigators will use biomarkers of early effects of re...
Detailed Description
Electronic cigarettes (e-cig) are increasingly popular among adult smokers and adolescent never smokers. Chemical analyses of e-cig vapor and liquid have shown the presence of many of the same carcino...
Eligibility Criteria
Inclusion
- Being male or female between the ages of 22-55;
- Being able to read and write in English and understand and give informed consent;
- Giving consent to strictly follow the study protocol throughout the study;
- Not planning to move, take an extended vacation, or undergo surgery during the study;
- Reporting smoking of \> 5 manufactured cigarettes per day for at least 1 year (applicable to participants who will undergo intervention with e-cig (Grp 1) or continue to smoke (Grp 2) only); and
- Presenting with an expired air CO measurement of \> 7 parts per million (ppm) at baseline (applicable to participants who will undergo intervention with e-cig (Grp 1) or continue to smoke (Grp 2) only).
Exclusion
- Having oral infection/inflammation, gum disease, dental decay, immune system disorders, diabetes, respiratory diseases (e.g., asthma), or kidney diseases;
- Having any unstable or significant medical condition (e.g., symptomatic heart conditions) in the past 12 months ;
- Having body mass index \< 18 kg/m2 or \> 40 kg/m2
- Being pregnant or having a baby in the past 12 months;
- Having uncontrolled mental illness or substance abuse (e.g., alcoholism) or inpatient treatment for those conditions in the past 12 months;
- Having used recreational or illicit drugs in the past 3 months;
- Having used any medication known to induce/inhibit CYP450 2A6 enzyme;
- Having any known allergy to propylene glycol/vegetable glycerin (applicable participants who will undergo intervention with e-cig (Grp 1) only); and
- Having another member of household participating in the study.
Key Trial Info
Start Date :
December 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2028
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT03750825
Start Date
December 1 2021
End Date
July 31 2028
Last Update
August 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Southern California, Health Sciences Campus
Los Angeles, California, United States, 90033